Gault Cheryl 4
4 · Rapport Therapeutics, Inc. · Filed Dec 1, 2025
Insider Transaction Report
Form 4
Gault Cheryl
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2025-11-26$1.80/sh+5,000$9,000→ 176,928 total - Sale
Common Stock
2025-11-26$30.10/sh−5,000$150,487→ 171,928 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-26−5,000→ 105,407 totalExercise: $1.80Exp: 2033-12-05→ Common Stock (5,000 underlying)
Footnotes (3)
- [F1]These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.